About Acerta Pharma

Dr Mortlock joins Acerta from his duties as Vice President, Global Projects and Alliances, IMED Oncology at AstraZeneca, where he is responsible for AstraZeneca’s small molecule oncology projects from start of lead optimization through to the end of Phase IIb clinical studies. Over 25 years in roles of increasing responsibility at AstraZeneca, he previously led the Oncology research group at Alderley Park (UK) and Reims (France) which included chemistry, bioscience and drug metabolism. He brings a wealth of medicinal chemistry, global development and project leadership experience involving kinase, protease, integrin, GPCR, nuclear hormone receptor and protein-protein interaction targets.

Dr Mortlock holds a first degree in chemistry and a PhD in organic synthesis from the University of Oxford and carried out post-doctoral work at the University of California, Berkeley. He has been an author on more than 50 scientific papers, patents and presentations.

Mark joined Acerta pharma in June of 2017 as Executive Director, Head of Clinical Science to lead the Acerta clinical science group for late-stage oncology-hematology.

Mark is a clinical development professional with over 20 years of experience in Oncology (Hematology, Immuno-oncology, and Solid Tumors). Mark has lead development teams as the Head of Clinical Operation at Corvus, Oncology Operation Lead at Gilead and the Hematology Disease Area Lead at Roche/Genentech. Mark has led both early and late-stage global development teams leading to successful clinical strategies and resulting in global regulatory filings in hematology/oncology for Rituxan/MabThera, Gazyva, and Venetoclax.

Mauricio has more than 15 years of professional experience in several business and financial leadership functions. Mauricio received his Bachelor of Finance in 1999 from the Universidad Panamericana and MBA from Universidad Anahuac in 2004 in Mexico City.

Mauricio joined AstraZeneca as FP&A Manager in Mexico and gained significant commercial experience in roles in the United Kingdom and Germany. He is known for his passion to be a strategic and tactical business partner and building high-performance teams.

Mauricio served as the CFO for CAMCAR MAC (Central America, Caribbean and Mid Andean Countries) based in Costa Rica where his responsibilities extended well beyond Finance. He relocated to Gaithersburg, MD, USA to join the GPPS area as the Therapeutic Area Finance Director for Infection, Neuroscience and Autoimmunity (INA) continuing to deliver additional value to mature brands and supported diverse initiatives for the pipeline portfolio, including TA strategy and portfolio prioritization.

Prior to joining AstraZeneca, Mauricio worked for companies such as General Electric, British Petroleum and the Mexican Stock Exchange in the areas of Planning and Financial Performance. During his free time Mauricio enjoys traveling, photography and playing soccer with his two boys.

Dr Soriot brings significant experience in established and emerging markets, strength of strategic thinking, a successful track record of managing change and executing strategy, and the ability to lead a diverse organization. He served as Chief Operating Officer of Roche’s pharmaceuticals division from 2010 to September 2012 and, prior to that, Chief Executive Officer of Genentech, a biologics business, where he led its successful merger with Roche. Pascal joined the pharmaceutical industry in 1986 and has worked in senior management roles in numerous major companies around the world. He is a doctor of veterinary medicine (École Nationale Vétérinaire d’Alfort, Maisons-Alfort) and holds an MBA from HEC, Paris.

Mr Dunoyer’s career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GlaxoSmithKline (GSK), has given him extensive industry experience, including finance and accounting; corporate strategy and planning; research and development; sales and marketing; business reorganization; and business development. Marc is a qualified accountant and joined AstraZeneca in 2013, serving as Executive Vice-President, GPPS from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK and (concurrently) Chairman, GSK Japan. He holds an MBA from HEC, Paris and a Bachelor of Law degree from Paris University.

Dr Stam joined Acerta Pharma in January 2018 as Vice President Research Europe & Site Head of Acerta’s R&D site in The Netherlands. Dr Stam has over 25 years of experience in pharmaceutical industry, and held executive positions in business development & licensing, R&D portfolio management, strategy, merger & acquisition research, and R&D at Merck & Co, Schering-Plough, and Organon.

Furthermore, as business lead, he played a pivotal role in setting up fundraising activities for, several biotech start-ups and spin-out companies. In several of these companies, he served as interim CEO, or member of the advisory board.

Dr Stam received an MSc degree in Chemistry, and a PhD in immunology/cancer research from the Free University Amsterdam & Netherlands Cancer Institute. Furthermore, he holds a Master's degree in Business Administration (MBA) and is a Certified Licensing Professional (CLP™).